Endogena Therapeutics, Inc.’s Post

In this #article with Manufacturing Chemist, our CEO, Thierry Van Nieuwenhove, discusses the impact of next-generation oral dosage therapeutics, AI technologies, and our #drugdevelopment platform on the #pharmaceutical industry. Read here: https://bit.ly/3R8ri7U

Our most popular stories of the year involve CRISPR therapies, generative AI, obesity drugs entering prime time, and changes in the Covid-19 landscape, signaling the biggest trends in the pharmaceutical and biotech industry. Read the full article below on Pharmaceutical-Technology: #globaldata #pharmaceuticaltechnology #CRISPR #AI #drugdiscovery #pharmaindustry https://lnkd.in/eaPgwarh

𝐌𝐚𝐫𝐤𝐞𝐭 𝐒𝐧𝐚𝐩𝐬𝐡𝐨𝐭 - 𝐈𝐧-𝐕𝐢𝐯𝐨 🔬📈 As Biologics overtake Small Molecule Drugs in popularity, the In-Vivo CRO market is becoming more widespread - projected to reach 𝐔𝐒𝐃 13.74 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 2033, 𝐠𝐫𝐨𝐰𝐢𝐧𝐠 𝐚𝐭 𝐚 𝐂𝐀𝐆𝐑 𝐨𝐟 8.34% 𝐟𝐫𝐨𝐦 2024 𝐭𝐨 2034. 𝐊𝐞𝐲 𝐓𝐚𝐤𝐞𝐚𝐰𝐚𝐲𝐬 👇 ➟ Non-Rodent segment expected to witness a significant CAGR over period ➟ GLP Toxicology segment looks to retain dominance during the forecast ➟ Asia Pacific is expected to witness the fastest CAGR during the forecast No doubt the likes of Jackson Laboratories, Crown Bioscience & Evotec will be looking to strengthen their dominance as times goes on - However, this opportunity most definitely gives a rise to the "Up & Commers" that are looking to assert a noticeable presence within the In-Vivo space. Very much looking forward to seeing what the market brings within the near future 👀 #drugdiscovery #invivo #preclinical

Unlock the future of drug discovery with “Unlocking Undruggable Targets!” This new eBook is your essential guide to overcoming the toughest challenges in drug development. Whether you're exploring new therapies or optimizing pipelines, you'll find the insights you need to stay ahead. #DrugDiscovery #Biotechnology #PharmaInnovation #UndruggableTargets

Targeting "undruggable" disease mechanisms is now within reach. Our latest eBook, "Unlocking Undruggable Targets", dives deep into how cutting-edge technologies are transforming the landscape of pharmaceutical research. Download your copy today. <<https://lnkd.in/gCayF6wC>>

Identifying and accelerating drug development is big business. The costs in this industry are significant and finding pathways to optimize using AI methods is top of mind in this fast and evolving industry. Deloitte found that the average cost of developing a new drug among the top 20 global #biopharmas it studied rose 15% ($298 million) last year, to approximately $2.3 billion. That figure includes the average cost of developing a candidate from discovery through clinical trials to the market. Many #biopharmaceutical companies are using #AI to speed up drug development. For example, machine-learning models are trained using information about the protein or #amino-acid sequence or 3D structure of previous drug candidates, and about properties of interest. https://lnkd.in/g3xQ8gkv

We'd like to thank DIA for their invaluable knowledge sharing in the article "AI Is Unearthing New Drug Candidates, But It Still Needs Human Oversight." At Acodis, we fully support the Human-in-the-Loop (HITL) approach, combining advanced AI with essential human expertise. This synergy enables us to help pharma organizations worldwide streamline drug development, reduce costs, and accelerate the delivery of life-saving treatments. 🌍💊 Thank you, DIA, for fostering innovation and collaboration in the pharmaceutical industry. 🚀 Read the Full Article here: https://lnkd.in/gNyndCZf

💡 How can we bridge the gap between preclinical studies and clinical success? This article, published in Nature Reviews Drug Discovery and written by MIMETAS' CEOs Jos Joore and Paul Vulto, explores how Organ-on-a-Chip (OoC) platform are impacting the pharmaceutical industry by doing just that. The publication details how these models offer precise platforms for better drug efficacy and safety predictions and help identify adverse drug effects and optimizing candidates. You'll also read how companies like Janssen, AstraZeneca, and Roche are leveraging OoCs for informed decision-making. Read the full article to see how OoCs are shaping the future of drug discovery and development. Read the article: https://lnkd.in/e-W_RtQ9 #DrugDiscovery #OrganOnChip #PharmaceuticalResearch #Biotech

Feature - Pharmaceutical Technology’s most-read stories of 2023 Our most popular stories of the year involve CRISPR therapies, generative AI, obesity drugs entering prime time, and changes in the Covid-19 landscape, signaling the biggest trends in the pharmaceutical and biotech industry. - https://lnkd.in/dJw-if2G #pharma #crispr #generativeai #obesitydrugs #covid19 #biotech #ai #aiinhealthcare #rna #drugdiscovery

#Alphafold is back in the news with these partnerships of IsoLabs. Drug making away from traditional methods will save research months in both protein structure discovery and the drug development itself. The one challenge/ gap of translating predicted structures into validated drug targets and effective therapeutics is being closed with such thoughtful partnerships. Overall, this truly is a step in the right direction to revolutionize the way humanity discovers and develops new and tailor-speciific drugs into the future. Its impact will likely be felt across various therapeutic areas, leading to faster, more efficient, and potentially more effective drug development for a range of diseases. #multiplesequencealignment #unsupervised #attention #evolutionary #deepmind